277316-24-2 Usage
Uses
Used in Pharmaceutical Research:
BOC-DAP is utilized as a building block in the synthesis of peptidoglycan-based antibiotics and peptidomimetic compounds. Its role in pharmaceutical research is crucial for the development of new antibiotics and the study of novel bioactive molecules.
Used in Organic Synthesis:
In the field of organic synthesis, BOC-DAP serves as an essential component for creating complex molecular structures. Its unique properties and functional groups facilitate the design and synthesis of various compounds with potential applications in different industries.
Used in Antimicrobial Applications:
BOC-DAP has been studied for its potential antimicrobial and antibacterial properties, making it an important molecule in the development of new antibiotics. Its ability to combat resistant bacteria and contribute to the fight against antibiotic resistance is a significant aspect of its use in this industry.
Used in Medicinal Chemistry:
BOC-DAP's unique structure and functional groups make it a valuable tool for designing and studying novel bioactive molecules in medicinal chemistry. Its application in this field aids in the discovery of new therapeutic agents and the advancement of medical treatments.
Check Digit Verification of cas no
The CAS Registry Mumber 277316-24-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,7,7,3,1 and 6 respectively; the second part has 2 digits, 2 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 277316-24:
(8*2)+(7*7)+(6*7)+(5*3)+(4*1)+(3*6)+(2*2)+(1*4)=152
152 % 10 = 2
So 277316-24-2 is a valid CAS Registry Number.
277316-24-2Relevant academic research and scientific papers
IMPROVED LINKERS FOR ANCHORING TARGETING LIGANDS
-
Page/Page column 12; 23-24, (2008/12/06)
An improved linker which lacks chiral centers between a hydrophobic anchor for coupling to lipid-based particles and a targeting agent has suitable hydrophobic/hydrophilic properties for use in vivo.
SIMULTANEOUS IMAGING OF CARDIAC PERFUSION AND A VITRONECTIN RECEPTOR TARGETED IMAGING AGENT
-
, (2008/06/13)
The present invention describes a method of concurrent imaging in a mammal comprising: a) administering to said mammal a vitronectin receptor targeted imaging agent and a perfusion imaging agent; and b) concurrently detecting the vitronectin receptor targ
Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent
-
, (2008/06/13)
The present invention describes a method of concurrent imaging in a mammal comprising: a) administering to said mammal a vitronectin receptor targeted imaging agent and a perfusion imaging agent; and b) concurrently detecting the vitronectin receptor targ
Vitronectin receptor antagonist pharmaceuticals
-
, (2008/06/13)
The present invention describes novel compounds of the formula: (Q)d—Ln—Ch, useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present
